JPH0544926B2 - - Google Patents

Info

Publication number
JPH0544926B2
JPH0544926B2 JP1125055A JP12505589A JPH0544926B2 JP H0544926 B2 JPH0544926 B2 JP H0544926B2 JP 1125055 A JP1125055 A JP 1125055A JP 12505589 A JP12505589 A JP 12505589A JP H0544926 B2 JPH0544926 B2 JP H0544926B2
Authority
JP
Japan
Prior art keywords
group
formula
hydrogen atom
serotonin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP1125055A
Other languages
English (en)
Japanese (ja)
Other versions
JPH02304022A (ja
Inventor
Masanori Osakabe
Hiroto Hara
Yoshikuni Tamao
Ryoji Kikumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14900708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0544926(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Chemical Industries Ltd filed Critical Mitsubishi Chemical Industries Ltd
Priority to JP1125055A priority Critical patent/JPH02304022A/ja
Priority to DE69011732T priority patent/DE69011732T2/de
Priority to EP90109336A priority patent/EP0398326B1/en
Priority to US07/524,983 priority patent/US5032614A/en
Publication of JPH02304022A publication Critical patent/JPH02304022A/ja
Publication of JPH0544926B2 publication Critical patent/JPH0544926B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP1125055A 1989-05-18 1989-05-18 セロトニン拮抗剤 Granted JPH02304022A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP1125055A JPH02304022A (ja) 1989-05-18 1989-05-18 セロトニン拮抗剤
DE69011732T DE69011732T2 (de) 1989-05-18 1990-05-17 Serotonin-Antagonist.
EP90109336A EP0398326B1 (en) 1989-05-18 1990-05-17 Serotonin antagonist
US07/524,983 US5032614A (en) 1989-05-18 1990-05-18 Serotonin antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1125055A JPH02304022A (ja) 1989-05-18 1989-05-18 セロトニン拮抗剤

Publications (2)

Publication Number Publication Date
JPH02304022A JPH02304022A (ja) 1990-12-17
JPH0544926B2 true JPH0544926B2 (enExample) 1993-07-07

Family

ID=14900708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1125055A Granted JPH02304022A (ja) 1989-05-18 1989-05-18 セロトニン拮抗剤

Country Status (4)

Country Link
US (1) US5032614A (enExample)
EP (1) EP0398326B1 (enExample)
JP (1) JPH02304022A (enExample)
DE (1) DE69011732T2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101509D0 (sv) * 1991-05-17 1991-05-17 Karobio Ab Receptor ligands
NO300539B1 (no) 1992-11-30 1997-06-16 Sankyo Co alfa,omega-diarylalkanderivater, med terapeutisk aktivitet for behandling og forhindring av sirkulasjonssykdommer og psykoser, og farmasöytiske preparater inneholdende disse derivater
ES2116681T3 (es) * 1994-03-18 1998-07-16 Senju Pharma Co Preparaciones oftalmicas para reducir la presion intraocular.
EP0790235A1 (en) 1996-02-15 1997-08-20 Sankyo Company Limited Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses
EP0813878B1 (en) * 1996-06-17 2002-02-06 Mitsubishi Chemical Corporation Lacrimation accelerating agent containing a serotonin ligand, especially aminoalkoxybibenzyl compounds
FR2827280B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2460777A1 (en) * 2001-09-26 2003-04-03 Mitsubishi Pharma Corporation Thrombus/thrombogenesis inhibitors
AU2003257591A1 (en) * 2002-08-30 2004-03-19 Mitsubishi Pharma Corporation Preventive and/or therapeutic agent for heart failure
JP2004250441A (ja) * 2003-01-31 2004-09-09 Mitsubishi Pharma Corp 血小板大凝集塊の形成阻害剤
JP2005053890A (ja) * 2003-07-22 2005-03-03 Mitsubishi Pharma Corp アディポネクチン濃度低下及び／又はｃ反応性蛋白濃度上昇及び／又はｉｌ−１８濃度上昇に起因する疾患の予防及び／又は治療剤。
KR20060128994A (ko) * 2004-02-02 2006-12-14 미쯔비시 웰 파마 가부시키가이샤 만성 뇌 순환 부전증의 예방 및(또는) 치료제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6021578B2 (ja) * 1977-10-07 1985-05-28 三菱化学株式会社 （オメガ−アミノアルコキシ）ビベンジル類
US4220603A (en) * 1977-10-07 1980-09-02 Mitsubishi Chemical Industries, Limited Pharmaceutically active (omega-aminoalkoxy)bibenzyls
JPS5520740A (en) * 1978-08-01 1980-02-14 Mitsubishi Chem Ind Ltd Aminoalkoxybibenzyl and its acid addition salt
JPS5832847A (ja) * 1981-08-20 1983-02-25 Mitsubishi Chem Ind Ltd （３−アミノプロポキシ）ビベンジル類

Also Published As

Publication number Publication date
EP0398326B1 (en) 1994-08-24
JPH02304022A (ja) 1990-12-17
EP0398326A3 (en) 1992-01-08
US5032614A (en) 1991-07-16
EP0398326A2 (en) 1990-11-22
DE69011732T2 (de) 1994-12-22
DE69011732D1 (de) 1994-09-29

Similar Documents

Publication Publication Date Title
US20090253747A1 (en) Remedy for sleep disturbance
US20110268699A1 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
WO2004067003A1 (ja) 動脈硬化及び高血圧症の予防及び治療のための医薬
RU96116134A (ru) Новые гетероциклические соединения
JPH0544926B2 (enExample)
US20020107244A1 (en) Combination treatment for depression
PT1487424E (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-il-amino)fenil]-benzamida para o tratamento doenças mediadas por ang ii
JP3408546B2 (ja) 抗喘息剤
JP2603023B2 (ja) ４−アミノ−１−（２−ピリジル）ピペリジン誘導体の利用
JP2001511763A (ja) 尿失禁の治療のための５−ｈｔ▲下１ａ▼受容体アンタゴニストの使用
JPH03264528A (ja) 抗不安薬
KR970009078B1 (ko) 항불안제
RU2419433C2 (ru) Средство для профилактики или лечения алкогольной зависимости и зависимости от лекарственных веществ
EP1200093B1 (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
JP4525964B2 (ja) 肺高血圧症予防治療剤
US20060094715A1 (en) 5-Ht4 receptor antagonists for the treatment of heart failure
Saxena Further characterization of 5‐hydroxytryptamine1‐like receptors mediating tachycardia in the cat: No apparent relationship to known subtypes of the 5‐hydroxytryptamine1 binding site
JP2008044871A (ja) 心血管疾患予防・治療剤
JPH06321899A (ja) １，２，５，６−テトラヒドロピリジン誘導体およびその製造法並びにその治療への用途
Davies et al. 3 4-Quinolones as Potential Cardiovascular Agents
JPH08502981A (ja) 高血圧の治療のための方法および（＋）ドキサゾシンの組成物
JP2955768B2 (ja) 新規なジアゾシン誘導体
US20040248914A1 (en) Method for the treatment of overactive bladder
JP2007512267A (ja) 高尿酸血症の治療のためのペンタジエン酸誘導体の使用
JP2005041801A (ja) 細胞移植療法後の予後改善剤

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090707

Year of fee payment: 16

EXPY Cancellation because of completion of term